BofA cuts Leidos stock rating on healthcare portfolio pressure By Investing.com

BofA Securities downgraded Leidos Holdings to Neutral from Buy and cut its price target sharply to $125 from $200, citing rising pressure across the company’s healthcare portfolio. Leidos shares were trading at $113.58, near the 52-week low of $113.28 and down 37% over the past six months. BofA still sees value in Leidos’ defense business, but expects investors to wait for execution before assigning full credit.

Analysis

The market is likely still underestimating how much of LDOS’s multiple was implicitly supported by a cleaner growth narrative in healthcare. Once that leg is questioned, the stock stops trading like a defense compounder and starts trading like a low-growth integrator with project risk, which mechanically compresses valuation faster than the earnings cuts themselves. The fact that the shares are already pressing long-term lows matters less as a “support level” and more as a signal that marginal sellers are now index/rebalance and fundamental holders de-risking, a setup that can persist for weeks even if defense backlog remains intact.

The second-order issue is timing: the defense wins are real, but they are long-dated and lumpy, while the healthcare pressure is nearer-term and visible in margin/forecast revisions. That creates a classic bad-news-can-hit-now, good-news-may-never-be-capitalized asymmetry. If the company needs multiple quarters to prove the defense mix can offset healthcare drag, the stock likely remains hostage to estimate cuts and a lower-quality narrative, especially as sell-side models converge toward a mid-teens EPS reality rather than prior optimistic trajectories.

A more interesting read-through is to adjacent federal IT and defense primes: if LDOS is discounted despite exposure to priority programs, investors may begin demanding proof-of-execution rather than backlog credit across the group. That can temporarily weigh on contractors with similar “promise vs. delivery” profiles, while benefiting pure-play defense names with cleaner organic growth and less healthcare exposure. The article also reinforces a subtle supply-chain signal: specialized software/cloud and mission systems providers tied to DoD modernization may get a relative valuation premium versus diversified integrators with legacy civilian exposure.

Contrarianly, the selloff may be partially overdone if healthcare pressure is a portfolio drag rather than a structural impairment, because defense demand is still being funded and the strategic categories cited are not discretionary. But the burden of proof has shifted sharply: until there is a visible quarter of margin stabilization and order conversion, this is a dead-money/negative drift setup rather than a value rebound candidate.

Key Decisions for Investors

• Short LDOS on rallies over the next 2-6 weeks; use prior support as a staging area for the trade, with downside toward the low-$100s if another estimate cut follows. Risk/reward favors staying with the trend until healthcare deterioration stops showing up in guidance.
• Pair trade: long pure-play defense/software primes with cleaner growth profiles vs. short LDOS over 1-3 months. The logic is valuation dispersion: market is likely to reward names where backlog converts cleanly and penalize diversified integrators with ambiguous margin mix.
• Buy LDOS put spreads for the next earnings cycle rather than outright puts. The main catalyst is not an immediate collapse but a sequence of downward revisions; defined-risk downside captures that while limiting theta bleed if the stock stabilizes.
• Avoid catching the knife until there is evidence of healthcare stabilization in the next quarterly print. A reversal likely requires 1-2 quarters of clean execution, not just contract announcements, so the trade horizon is months, not days.